Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Background LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce
bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM) …

Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐
escalation regimens in patients with type 2 diabetes. Materials and Methods In this double …

Ambiguity regarding the role of glucose-dependent insulinotropic polypeptide (GIP) in
obesity arises from conflicting reports asserting that both GIP receptor (GIPR) agonism and …

Glucagon-like peptide 1 receptor (GLP-1R) agonists decrease body weight and improve
glycemic control in obesity and diabetes. Patient compliance and maximal efficacy of GLP-1 …

We present the results of a GWAS of food liking conducted on 161,625 participants from the
UK-Biobank. Liking was assessed over 139 specific foods using a 9-point scale. Genetic …

Objective Structurally-improved GIP analogs were developed to determine precisely
whether GIP receptor (GIPR) agonism or antagonism lowers body weight in obese mice …